Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences, a wholly owned licensing subsidiary of IR BioSciences Holdings has commenced collaboration with DelSite Biotechnologies, a wholly owned subsidiary of Carrington Laboratories, to develop a new vaccine adjuvant system that provides both immediate and sustained immunostimulation for more effective protection against a variety of transmittable pathogens.
Subscribe to our email newsletter
With an initial focus on an influenza virus vaccine, the collaboration will determine if the combination of ImmuneRegen’s vaccine adjuvant compound, Viprovex, and DelSite’s unique adjuvant system, based on the polymer GelSite, can potentially augment the ability of vaccine products to produce the enhanced immune response.
Michael Wilhelm, president and CEO of ImmuneRegen, said: “Our work with DelSite supports the development of vaccines and adjuvants that can be quickly and easily self-administered.”